Phasefocus3 Aug 2022 15:29
I thought I'd start a thread on what actually matters to BRH, just to be controversial.
For those who didn't know, or who had forgotten: BRH is an investment company, not a COVID company called Paraytec.
Braveheart have 18 listed investments and have absorbed 2 small ones into their accounts as effectively owned.
Lifted directly from the year end results:
"Two investments (being Kirkstall and Paraytec) that are considered as Strategic Investments by the Board are now deemed to be 'controlled' by the Company and as a result of this, those companies have been consolidated into Braveheart's accounts (but remain categorised by management as Strategic Investments). At the year end, the value of these two investments was £220,622 (2021: £220,622)"
So there you go folks, max. value of Paraytec is just over £200k - revenue £0.
"The fair value of the directly held portfolio, excluding the two companies now consolidated into the Company's accounts, was £4,716,080 (2021: £613,847)."
That's a big rise in carrying value isn't it? Anybody know what drove this revaluation?
Correct answer - Phasefocus!! Well done to all of you who got that right.
BRH has very little revenue and will rely on a profitable sale to return anything to investors. Given the last RNS spelt out that nobody will buy the CX300, I wonder what our best chance of a sale is?
In all the melee and hysteria about Paraytec and their "magic machine" it might be worth reminding a few of the reality here, and in truth the MCAP right now reflects this reality.